Organon & Co
OGN
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Organon & Co. (Organon) is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The Company sells these products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. It operates approximately six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • 3 days ago • OGN
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Zacks Investment Research • 6 days ago • OGN
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Business Wire • 12 days ago • OGN
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
Zacks Investment Research • 19 days ago • OGN
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Business Wire • 20 days ago • OGN
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.